Literature DB >> 3365688

Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.

G Bruchelt1, R Girgert, J Buck, H Wolburg, D Niethammer, J Treuner.   

Abstract

As we have reported recently, the human neuroblastoma cell line SK-N-SH is able to take up and store m-iodobenzylguanidine (mIBG). This is in contrast to several other neuroblastoma cell lines, among which are SK-N-LO cells. Both cell lines were used in cell killing experiments with unlabeled and radioactive-labeled mIBG. Using 1-200 microCi m-[131I]IBG (1 h incubation time), only SK-N-SH cells could to a large extent be destroyed in a dose-dependent manner. This effect is completely caused by the radioactive labeling of the molecule, because unlabeled mIBG proved not to be toxic in the concentration range used in experiments with radiolabeled mIBG (30 nM-3 microM). The killing effect was strongly reduced when m-[131I]IBG with low specific activity (0.2-0.3 mCi/mg) was used instead of 20-30 mCi/mg. Similar effects in both cell lines were obtained using m-[131I]-and m-[125I]IBG. SK-N-SH cells that survived a first treatment with m-[131I]IBG were less sensitive to a second treatment. SK-N-LO cells were more sensitive against m-[131I]- and m-[125I]IBG than SK-N-SH cells if both cell lines are exposed to these radioactive compounds over a long period of time (24 h). The reason that only SK-N-SH cells could be destroyed in short-term incubation experiments is that mIBG is stored for approximately 7 days in these cells only. SK-N-LO cells could only be destroyed to a significant degree if m-[131I]IBG was permanently present in the test system. Bone marrow stem cells (CFU-c) also proved to be sensitive against m-[131I]IBG, although the effects were less pronounced than on SK-N-SH cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365688

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

Review 2.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

3.  Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.

Authors:  S H Cunningham; R J Mairs; T E Wheldon; P C Welsh; G Vaidyanathan; M R Zalutsky
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

4.  Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

Authors:  G Vaidyanathan; H S Friedman; S T Keir; M R Zalutsky
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

Review 5.  Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Authors:  Keri A Streby; Nilay Shah; Mark A Ranalli; Anne Kunkler; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.